|
| Register for our Free Newsletters |
|
 |
|
|
|
|
|
|
|
|
| Other Carouselweb publications |
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
Accuray extends treatment options for patients in Finland
|
|
Accuray
: 03 April, 2012 (Application Story) |
|
|
Kuopio University Hospital in Kuopio, Finland is beginning to treat patients with Accuray's CyberKnife Robotic Radiosurgery System, providing Finland and the Nordic countries with the most advanced option in radiosurgery and stereotactic body radiotherapy (SBRT). |
|
The CyberKnife System allows Kuopio University to offer patients a non-invasive, personalized option for treatment of tumors throughout the body, including brain, spine, lung, prostate, liver, pancreas and breast tumours, enabling the hospital to offer treatments to a new group of patients.
"When looking for ways to expand our radiation oncology offerings, we looked for technology capable of effectively treating tumours anywhere in the body while sparing normal tissue, critical structures and preserving quality of life for patients," said Jan-Erik Palmgren, Medical Physicist and CyberKnife project lead at Cancer Center, Kuopio University Hospital. "We found that the CyberKnife System allows us to offer an effective alternative to surgery for patients seeking a non-surgical option or for those who may be poor surgical candidates. We can now offer a new treatment option for many patients with advanced stage and recurrent cancers who are left with few or no options. The CyberKnife System's ability to automatically track and correct for tumor motion throughout the body ensures these patients will have the best opportunity for a superior outcome."
Kuopio University's hospital strives to provide access to a large, widespread population that can require patients to travel several hours for treatment.
Therefore it is essential that Kuopio University can now provide treatment options that are both effective and convenient. For some cancers, such as prostate, lung, spine and liver cancer, CyberKnife SBRT, delivered over a single week, has been shown to be equally or more effective when compared to six to eight weeks of conventional radiation therapy treatment. This added convenience translates into increased treatment access and compliance for patients who prior to the availability of the CyberKnife System may not have attempted or completed their treatment due to the burden of weeks of travel.
"We are pleased to extend the benefits of CyberKnife radiosurgery and SBRT to patients in Finland and the surrounding region," said Euan Thomson, PhD, President and Chief Executive Officer of Accuray. "Through continued clinically driven innovation that is focused on patients, we look forward to further expanding treatment options for leading centres like Kuopio University Hospital and improving access to treatment solutions that will improve patient outcomes and care.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
